Triflusal posttreatment inhibits glial nuclear factor-κB, downregulates the glial response, and is neuroprotective in an excitotoxic injury model in postnatal brain

Stroke

Volumn 32, Issue 10, 2001, Pages 2394-2402

  Acarin, Laia ^a   González, Berta ^a   Castellano, Bernardo ^a  

^a UNIVERSITAT AUTÒNOMA DE BARCELONA   (Spain)

Author keywords

Anti inflammatory agents, nonsteroidal; Antiplatelet agents; Astrocytes; Excitotoxicity; Microglia; Neuroglia; Neuroprotection; Newborn; Salicylates; Stroke,experimental; Transcription factors

Indexed keywords

ANTITHROMBOCYTIC AGENT; GLIAL FIBRILLARY ACIDIC PROTEIN; IMMUNOGLOBULIN ENHANCER BINDING PROTEIN; LECTIN; N METHYL DEXTRO ASPARTIC ACID; STAT3 PROTEIN; TOLONIUM CHLORIDE; TOMATO LECTIN; TRIFLUSAL; UNCLASSIFIED DRUG;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; BRAIN INJURY; CONTROLLED STUDY; DRUG EFFECT; GLIA CELL; HISTOCHEMISTRY; IMMUNOCYTOCHEMISTRY; MACROGLIA; MICROGLIA; NERVE CELL DEGENERATION; NEUROPROTECTION; NONHUMAN; PRIORITY JOURNAL; PROTEIN EXPRESSION; RAT; STROKE; SURVIVAL; TREATMENT OUTCOME; TREATMENT PLANNING;

EID: 0034797396     PISSN: 00392499     EISSN: None     Source Type: Journal    
DOI: 10.1161/hs1001.097243     Document Type: Article

References (60)

1. Enhancement of immunoreactivity for NF-kappa B in human cerebral infarctions
2. Activation of nuclear factor-kappaB in the rat brain after transient focal ischemia
3. Stat3 and NFκB glial expression after excitotoxic damage to the postnatal brain
4. STAT3 and NFκB activation precedes glial reactivity in the excitotoxically injured young cortex but not in the corresponding distal thalamic nuclei
5. Induction of NF-κB-like transcription factors in brain areas susceptible to kainate toxicity
6. Increased cortical nuclear factor-κB (NFκB) DNA binding activity after traumatic brain injury in rats
7. Enhancement of immunoreactivity for NF-κB in the hippocampal formation and cerebral cortex of Alzheimer's disease
8. Nuclear translocation of NF-kappa B is increased in dopaminergic neurons of patients with Parkinson disease
9. Transcription factor NF-kappa B is activated in microglia during experimental autoimmune encephalomyelitis
10. Nuclear factor-kappa B/Rel proteins: A point of convergence of signalling pathways relevant in neuronal function and dysfunction
11. Nuclear factor-kappa B contributes to excitotoxin-induced apoptosis in rat striatum
12. NF-kappa B is activated and promotes cell death in focal cerebral ischemia
13. Inhibition of NF-kappa B potentiates amyloid beta-mediated neuronal apoptosis
14. Activation of NF-kappa B protects hippocampal neurons against oxidative stress-induced apoptosis: Evidence for induction of manganese superoxide dismutase and suppression of peroxynitrite production and protein tyrosine nitration
15. Lack of the p50 subunit of nuclear factor-kappaB increases the vulnerability of hippocampal neurons to excitotoxic injury
16. Janus faces of NF-kappa B: Neurodestruction versus neuroprotection
17. Pathobiology of ischaemic stroke: An integrated view
18. Brain inflammation in Alzheimer disease and the therapeutic implications
19. Transcriptional responses to polypeptide ligands: The JAK-STAT pathway
20. NF-κB: A crucial transcription factor for glial and neuronal cell function
21. Pro-inflammatory signaling: Last pieces in the NF-kappa B puzzle
22. Role of excitotoxins in developmental neuropathology
23. Excitotoxic cell death
24. Kainic acid-induced activation of nuclear factor-kappaB in rat hippocampus
25. Triflusal
26. 4-Trifluoromethyl derivatives of salicylate, triflusal and its main metabolite 2-hydroxy-4-trifluoromethylbenzoic acid, are potent inhibitors of nuclear factor kappaB activation
27. Inhibition of cyclooxygenase-2 expression by 4-trifluoromethyl derivatives of salicylate, triflusal, and its deacetylated metabolite, 2-hydroxy-4-trifluoromethylbenzoic acid
28. Oral administration of the anti-inflammatory substance triflusal results in the downregulation of constitutive transcription factor NF-κB in the postnatal rat brain
29. Primary cortical glial reaction versus secondary thalamic glial response in the excitotoxically injured young brain: Astroglial response and metallothionein expression
30. Primary cortical glial reaction versus secondary thalamic glial response in the excitotoxically injured young brain: Microglial/macrophage response and MHC class I and II expression
31. Demonstration of poly-N-acetyl lactosamine residues in ameboid and ramified microglial cells in rat brain by tomato lectin binding
32. Glial response to excitotoxic injury in the immature rat brain
33. Free radicals, calcium, and the synaptic plasticity cell death continuum: Emerging roles of the transcription factor NF kappa B
34. Roles of nuclear factor kappaB in neuronal survival and plasticity
35. Kainic acid-induced apoptosis in rat striatum is associated with nuclear factor-kappaB activation
36. Neuroprotection by aspirin and sodium salicylate through blockade of NF- kappaB activation
37. Acetylsalicylic acid increases tolerance against hypoxic and chemical hypoxia
38. Aspirin and salicylate protect against MPTP-induced dopamine depletion in mice
39. Neuroprotective effects of acetylsalicylic acid in an animal model of focal brain ischemia
40. Cyclo-oxygenase-2 gene expression in neurons contributes to ischemic brain damage
41. A cyclooxygenase-2 inhibitor attenuates white matter damage in chronic cerebral ischemia
42. Central nervous system DNA fragmentation induced by the inhibition of nuclear factor kappa B
43. Inflammation and glial responses in ischemic brain lesions
44. Involvement of free radicals in excitotoxicity in vivo
45. Neuronal, astroglial and microglial cytokine expression after an excitotoxic lesion in the immature rat brain
46. Glial fibrillary acidic protein transcription responses to transforming growth factor-beta1 and interleukin-1beta are mediated by a nuclear factor-1-like site in the near-upstream promoter
47. A 3′ cis-acting element is involved in tumor necrosis factor-α gene expression in astrocytes
48. Cytokine regulation of interleukin-6 gene expression in astrocytes involves activation of an NF-kappa B-like nuclear protein
49. Cell type-specific regulation of major histocompatibility complex (MHC) class I gene expression in astrocytes, oligodendrocytes, and neurons
50. Activation of NF-kappa B and induction of vascular cell adhesion molecule-1 and intracellular adhesion molecule-1 expression in human glial cells by IL-1: Modulation by antioxidants
51. IL-1-induced iNOS expression in human astrocytes via NF-kappa B
52. Expression and regulation of cyclooxygenase-2 in rat microglia
53. Signalling through the JAK-STAT pathway in the developing brain
54. Induction of Stat3, a signal transducer and transcription factor, in reactive microglia following transient focal cerebral ischaemia
55. Activation of the JAK/STAT pathway following transient focal cerebral ischemia: Signaling through Jak1 and Stat3 in astrocytes
56. Inhibition of caspase-1-like activity by Ac-tyr-val-ala-asp-chloromethyl ketone induces long-lasting neuroprotection in cerebral ischemia through apoptosis reduction and decrease of proinflammatory cytokines
57. Tetracyclines inhibit microglial activation and are neuroprotective in global brain ischemia
58. Cyclopentenone prostaglandin 15-deoxy-delta(12,14)-prostaglandin J(2) acts as a general inhibitor of inflammatory responses in activated BV-2 microglial cells
59. The effects of a novel NSAID on chronic neuroinflammation are age dependent
60. Neuroprotection achieved with a novel proteasome inhibitor which blocks NF-kappa B activation